DrSN’s annual Industry Issues Summit to be held Dec. 4
NEW YORK Key executives from several leading suppliers and retailers will convene here next month to attend Drug Store News’ 9th Annual Industry Issues Summit—an invaluable supplier-retailer panel discussion that serves as a platform for the exchange of ideas on the issues that shape chain pharmacy.
The event will be held Dec. 4 at the Flatotel at 135 West 52nd Street in New York. Capping off the afternoon will be the 5th Annual Diabetes Roundtable.
“The Issues Summit and the Diabetes Roundtable are great chances to talk to retail leaders and learn about new business opportunities … it’s six hours of productive vendor/retailer conversation,” said John Kenlon, publisher of Drug Store News.
The lively panel discussion will center on industry issues and challenges facing both retailers and suppliers, and will offer attendees insight into how to overcome those feats, develop stronger partnerships, plan and executive more efficiently, and bolster sales and market share.
Retail panelists include Chuck Fehlig of Wal-Mart; David D’Arezzo and Kaliroi Brodin of Duane Reade; Bryan Shirtliff and Ernest Richardsen of Rite Aid; Dan Funk of Supervalu; Dave Fong and Brian Hille of Safeway; Charles Burnett of Costco; Todd Vasos of Longs Drug Stores; Barbara Poling of Kmart; Mark Doerr and Robb Ayshford of Kmart/Sears; Jerry Kuske of Katz Group; John Fegan of Ahold; and Chrissy Ellegood of Medicine Shoppe.
The event also will feature two keynote speakers. Peter Hoyt, president of Hoyt Publishing and executive director of In-Store Marketing Institute, will talk about “Shopper Marketing.” Dr. Stephen Bruton, director of faculty development at Cabarrus/NorthEast Medical Center Family Practice Residency, will talk about “The New Diabetes Epidemic: What Retail Pharmacy Needs to Know.”
Mass. court levies combined $13.6 million against AstraZeneca, Bristol-Myers Squibb
BOSTON A federal court in Massachusetts entered $12.9 million in damages against AstraZeneca and $695,594 against Bristol-Myers Squibb for the state’s class action members in a suit related to marketing the spread of certain drugs, according to law firms.
The judge, Patti B. Saris, found that AstraZeneca marketed the spread on its Zoladex drug, which is used to treat prostate cancer, selling it based on its profitability to doctors’ offices. She also found that less than 10 percent of Bristol-Myers Squibb’s sales were made within 5 percent of its list price, according to DowJones.
AstraZeneca and Bristol-Myers Squibb intend to appeal the ruling, which covers Massachusetts’s class-action participants.
Eli Lilly’s depression care program receives certification
INDIANAPOLIS Eli Lilly has received Program Design Certification from the National Committee for Quality Assurance for its Tools that Empower Depression Care Management Program.
Tools that Empower Depression Care Management Program is designed for managed care organizations to assist in further driving the standard of patient care around major depressive disorder. It helps identify members with major depressive disorder and offers educational resources to support treatment.
“Tools that Empower is part of Lilly’s commitment to our customers to help reduce patient risk and create an environment of continuous improvement for patient care,” said Jack Bailey, vice president, Lilly’s Business to Business division. “The NCQA certification validates the helpful tools provided by the program.”